Known lymphocytes (CCL19, CCL20, CCL21, and CCL22) and DCs (CXCL12) chemokines were also expressed at significantly higher levels at disease stabilization, while chemokines that recruit myeloid cells (CCL3, CCL4, CCL5), Treg (CCL4) and activated T lymphocytes (CXCL9, CXCL10, and CXCL11) were expressed at significantly higher levels during tumor progression (Figure 2). This evidence concerns the gene CCL22 and neoplasm.